ABO-incompatible heart transplantation.

Area of Science:

• Pediatric Cardiology
• Transplantation Immunology
• Immunology

Background:

• ABO-incompatible heart transplantation (HTx) has transitioned from experimental to standard practice in pediatric care.
• Research highlights the role of the immature immune system in enhancing graft acceptance and tolerance in childhood ABOi HTx.

Purpose of the Study:

• To review the clinical evolution and immunological insights of ABO-incompatible heart transplantation in children.
• To discuss current practices, limitations, and future directions for ABOi HTx.

Main Methods:

• Review of multicenter clinical experiences and immunological research in pediatric ABOi HTx.
• Analysis of long-term follow-up data on graft survival, rejection, and immune responses.
• Exploration of mechanisms contributing to tolerance, including B-cell and complement system interactions.

Main Results:

• ABOi HTx demonstrates comparable actuarial survival and freedom from rejection and graft vasculopathy to ABO-compatible HTx.
• Reduced antibody production and B-cell immunity towards donor blood groups are observed long-term.
• Mechanisms of tolerance involve B-cell memory, complement system interplay, and improved understanding of ABH antigens.

Conclusions:

• Pediatric ABOi HTx is a safe and effective option with outcomes matching ABO-compatible transplants.
• The immature immune system plays a crucial role in achieving graft acceptance and tolerance.
• Further research may expand ABOi HTx applicability to other age groups and organ transplants, potentially influencing HLA responses.